Rafael Rosell Selected Research

Platinum

12/2023	Olaparib maintenance versus placebo in platinum-sensitive non-small cell lung cancer: the Phase 2 randomized PIPSeN trial.
10/2022	Therapy for Stage IV Non-Small-Cell Lung Cancer Without Driver Alterations: ASCO Living Guideline.
1/2020	Efficacy and Safety of Pembrolizumab Plus Docetaxel vs Docetaxel Alone in Patients With Previously Treated Advanced Non-Small Cell Lung Cancer: The PROLUNG Phase 2 Randomized Clinical Trial.
1/2019	Association of PALB2 Messenger RNA Expression with Platinum-Docetaxel Efficacy in Advanced Non-Small Cell Lung Cancer.
1/2018	Genomic profiling in advanced stage non-small-cell lung cancer patients with platinum-based chemotherapy identifies germline variants with prognostic value in SMYD2.
6/2017	Anaplastic lymphoma kinase inhibitors in phase I and phase II clinical trials for non-small cell lung cancer.
3/2017	Low RAP80 mRNA expression correlates with shorter survival in sporadic high-grade serous ovarian carcinoma.
1/2017	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy.
4/2016	Prognostic Effect of Tumor Lymphocytic Infiltration in Resectable Non-Small-Cell Lung Cancer.
1/2016	SMARCA4/BRG1 Is a Novel Prognostic Biomarker Predictive of Cisplatin-Based Chemotherapy Outcomes in Resected Non-Small Cell Lung Cancer.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Rafael Rosell Research Topics

Disease

271	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 02/2024 - 02/2001
191	Neoplasms (Cancer) 02/2024 - 02/2001
121	Lung Neoplasms (Lung Cancer) 01/2024 - 02/2002
40	Adenocarcinoma of Lung 02/2024 - 06/2005
18	Disease Progression 01/2022 - 10/2003
14	Melanoma (Melanoma, Malignant) 03/2023 - 02/2006
13	Breast Neoplasms (Breast Cancer) 12/2016 - 10/2004
11	Neoplasm Metastasis (Metastasis) 09/2022 - 11/2011
10	Adenocarcinoma 10/2019 - 03/2004
8	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 06/2010
7	Brain Neoplasms (Brain Tumor) 12/2021 - 07/2013
7	Circulating Neoplastic Cells 01/2019 - 04/2013
6	Carcinogenesis 01/2023 - 12/2005
6	Ovarian Neoplasms (Ovarian Cancer) 12/2016 - 07/2002
6	Neutropenia 03/2012 - 12/2002
5	Sarcoma (Soft Tissue Sarcoma) 02/2023 - 06/2012
5	Diarrhea 02/2021 - 03/2004
5	Colorectal Neoplasms (Colorectal Cancer) 12/2017 - 04/2002
5	Stomach Neoplasms (Stomach Cancer) 03/2017 - 10/2011
5	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 09/2012 - 02/2001
5	Febrile Neutropenia 11/2008 - 12/2002
4	Glioblastoma (Glioblastoma Multiforme) 10/2021 - 04/2003
4	Hypersensitivity (Allergy) 03/2017 - 10/2004
3	Pneumonia (Pneumonitis) 01/2022 - 11/2017
3	Leukemia 01/2019 - 02/2001
3	Xeroderma Pigmentosum (Kaposi's Disease) 01/2017 - 08/2003
3	Exanthema (Rash) 02/2016 - 03/2012

Drug/Important Bio-Agent (IBA)

82	ErbB Receptors (EGF Receptor)IBA 02/2024 - 03/2004
63	Tyrosine Kinase InhibitorsIBA 12/2023 - 03/2004
45	Cisplatin (Platino)FDA LinkGeneric 07/2023 - 02/2002
43	Messenger RNA (mRNA)IBA 01/2024 - 07/2002
42	Biomarkers (Surrogate Marker)IBA 12/2023 - 04/2002
37	Erlotinib Hydrochloride (CP 358,774)FDA Link 01/2024 - 03/2006
33	PlatinumIBA 12/2023 - 06/2004
29	DNA (Deoxyribonucleic Acid)IBA 01/2021 - 01/2003
22	Immune Checkpoint InhibitorsIBA 02/2024 - 09/2015
21	Gemcitabine FDA Link 04/2020 - 02/2002
21	Docetaxel (Taxotere)FDA Link 01/2020 - 12/2002
20	Gefitinib (Iressa)FDA Link 02/2021 - 03/2004
19	osimertinibIBA 01/2024 - 01/2017
19	Proteins (Proteins, Gene)FDA Link 01/2021 - 03/2006
18	Cell-Free Nucleic AcidsIBA 01/2021 - 12/2005
15	Anaplastic Lymphoma KinaseIBA 03/2021 - 04/2014
14	CrizotinibIBA 01/2021 - 12/2011
12	Protein-Tyrosine Kinases (Tyrosine Kinase)IBA 02/2024 - 06/2005
12	RNA (Ribonucleic Acid)IBA 01/2023 - 01/2009
12	Phosphotransferases (Kinase)IBA 01/2022 - 02/2010
12	Pemetrexed (MTA)FDA Link 01/2016 - 04/2002
11	AntibodiesIBA 02/2023 - 12/2010
10	VaccinesIBA 12/2022 - 02/2006
9	LigandsIBA 01/2020 - 11/2011
9	Carboplatin (JM8)FDA LinkGeneric 01/2016 - 08/2003
8	ParaffinIBA 12/2023 - 07/2002
8	Vinorelbine (Navelbine)FDA LinkGeneric 01/2019 - 12/2002
7	Bevacizumab (Avastin)FDA Link 09/2021 - 06/2010
6	Monoclonal AntibodiesIBA 02/2024 - 01/2015
6	Microtubule-Associated Proteins (Microtubule-Associated Protein 2)IBA 02/2024 - 02/2001
6	Epidermal Growth Factor (EGF)IBA 09/2022 - 11/2002
6	Circulating Tumor DNAIBA 11/2021 - 01/2016
6	dacomitinibIBA 02/2021 - 09/2012
6	pembrolizumabIBA 10/2020 - 01/2015
6	Fluorouracil (Carac)FDA LinkGeneric 04/2020 - 04/2002
6	Ribonucleotide Reductases (Ribonucleotide Reductase)IBA 01/2017 - 12/2002
6	Paclitaxel (Taxol)FDA LinkGeneric 07/2011 - 08/2003
5	Tumor Biomarkers (Tumor Markers)IBA 01/2022 - 08/2002
5	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 08/2016 - 06/2013
4	Circular RNAIBA 12/2023 - 01/2022
4	NivolumabIBA 10/2022 - 01/2015
4	Metformin (Glucophage)FDA LinkGeneric 06/2022 - 11/2019
4	AfatinibIBA 03/2022 - 01/2014
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2021 - 02/2008
4	alectinibIBA 01/2021 - 06/2015
4	B7-H1 AntigenIBA 10/2020 - 09/2015
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 09/2019 - 06/2013
4	Irinotecan (Camptosar)FDA LinkGeneric 11/2017 - 12/2002
3	Programmed Cell Death 1 ReceptorIBA 02/2024 - 09/2015
3	trametinibIBA 01/2024 - 08/2016
3	Formaldehyde (Formol)FDA Link 12/2023 - 01/2016
3	durvalumabIBA 01/2023 - 01/2020
3	Phosphoric Monoester Hydrolases (Phosphatases)IBA 11/2020 - 01/2019
3	dabrafenibIBA 09/2019 - 06/2013
3	Platinum Compounds (Compounds, Platinum)IBA 03/2017 - 05/2007
3	Cancer VaccinesIBA 12/2015 - 02/2006
3	Indicators and Reagents (Reagents)IBA 05/2015 - 10/2004
3	Cetuximab (Erbitux)FDA Link 02/2014 - 12/2002
3	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2013 - 02/2001
3	EnzymesIBA 06/2013 - 07/2003
3	Codon (Codons)IBA 06/2011 - 01/2003
3	Epirubicin (Ellence)FDA LinkGeneric 03/2010 - 11/2004
2	olaparibIBA 12/2023 - 12/2020

Therapy/Procedure

116	Drug Therapy (Chemotherapy) 02/2023 - 02/2001
114	Therapeutics 02/2024 - 02/2001
44	Immunotherapy 02/2024 - 01/2015
14	Adjuvant Chemotherapy 01/2019 - 02/2001
9	Radiotherapy 12/2021 - 01/2006
6	Neoadjuvant Therapy 12/2018 - 04/2002
3	Precision Medicine 10/2020 - 10/2013
3	Aftercare (After-Treatment) 01/2020 - 07/2002
3	Chemoradiotherapy 01/2019 - 01/2015
3	Induction Chemotherapy 01/2017 - 10/2007